['urinary tract infections']
['cefepime 1g - 2g / aai101 0.5g - 0.75g', 'cefepime 1 g or cefepime 2 g']

        Inclusion criteria:

        • Male or female patients with clinical signs and/or symptoms of cUTI or acute
        pyelonephritis that were expected to require hospitalization and initial treatment with at
        least 7 days of i.v.

        antibiotics.

        Exclusion criteria:

          -  Patients with concurrent infection that would interfere with evaluation of response to
             the study antibiotics;

          -  Patients needing concomitant systemic antimicrobial agents in addition to those
             designated in the various study treatment groups;

          -  Patients receiving effective antibacterial drug therapy for any indication for a
             continuous duration of >24 hours during the previous 72 hours before the
             study-qualifying baseline urine was obtained or receiving any amount of potentially
             therapeutic antibacterial therapy after collection of the pre-treatment baseline urine
             culture and before administration of the first dose of study drug;

          -  Patients likely to require the use of an antibiotic for cUTI or acute pyelonephritis
             prophylaxis during participation in the study;

          -  Patients with confirmed fungal urinary tract infection at the screening visit (with
             ≥103 fungal colony forming units [CFU]/mL); or

          -  Patients with intractable urinary infection at baseline that the Investigator
             anticipated would require >10 days of study drug therapy were excluded from
             participation
      